Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 1:58 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–47 of 47 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Enterovirus Infection Clear all

Conditions: Diphtheria, Hepatitis B, Poliomyelitis, Pertussis, Tetanus
Interventions: DTaP-Hep B-IPV Vaccine, Monovalent Hep B Vaccine, Placebo; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Up to 5 Days
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Torrance, California

Conditions: Chronic Hepatitis C Virus
Interventions: LDV/SOF, RBV; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 647 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 52
States / cities: Birmingham, Alabama • La Jolla, California • Los Angeles, California + 49 more

Conditions: Congenital Heart Disease, Viremia, Virus Diseases, Enterovirus, Enterovirus Infections, Heart Defects, Congenital, Heart Diseases, Prenatal Infection, Diabetes, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Diabetes Mellitus, Pregnancy in Diabetic, Pregnancy Complications, Prenatal
Interventions: Stool and Blood Specimen Collection, Follow-up Medical Record Review; Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 114 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 2
States / cities: St Louis, Missouri

Conditions: Enterovirus, Rhinovirus
Interventions: Nitazoxanide, Placebo; Drug
Lead sponsor: Romark Laboratories L.C.; Industry
Eligibility: 12 Years and older
Enrollment: 1,756 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 43
States / cities: Birmingham, Alabama • Pelham, Alabama • Hot Springs, Arkansas + 36 more

Conditions: Post-polio Syndrome
Interventions: Flebogamma® 5% DIF, Placebo; Biological · Drug
Lead sponsor: Instituto Grifols, S.A.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 191 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 4
States / cities: St Louis, Missouri • Syracuse, New York • Philadelphia, Pennsylvania + 1 more

Conditions: Tetanus, Diphtheria, Pertussis, Measles, Polio
Interventions: Diphtheria and Tetanus Toxoids and Acellular Pertussis + Measles, Mumps, Rubella + Varicella Virus, Diphtheria and Tetanus Toxoids and Acellular Pertussis + Poliovirus + MMR + Varicella Virus; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 4 Years to 6 Years
Enrollment: 3,372 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 71
States / cities: Birmingham, Alabama • Pinson, Alabama • Trussville, Alabama + 60 more

Conditions: Postpoliomyelitis Syndrome
Interventions: Modafinil; Drug
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Herpangina, Gingivostomatitis, Hand, Foot and Mouth Disease
Interventions: Sucralfate, Placebo, Acetaminophen, Ibuprofen; Drug · Other
Lead sponsor: University of Texas at Austin; Other
Eligibility: 6 Months to 5 Years
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Hepatitis A
Interventions: hepatitis A vaccine; Biological
Lead sponsor: Centers for Disease Control and Prevention; Federal
Eligibility: 6 Months to 25 Years
Enrollment: 248 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1996 – 2001
U.S. locations: 2
States / cities: Anchorage, Alaska

Conditions: Polio
Interventions: dmLT, fIPV; Biological
Lead sponsor: University of Vermont; Other
Eligibility: 18 Years to 45 Years
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Burlington, Vermont

Conditions: Chronic Hepatitis C Virus
Interventions: LDV/SOF, RBV; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 870 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 53
States / cities: Birmingham, Alabama • La Jolla, California • Long Beach, California + 50 more

Conditions: Hepatitis A
Interventions: Havrix™, Infanrix™, ActHIB™; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Months to 13 Months
Enrollment: 468 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2007
U.S. locations: 22
States / cities: Phoenix, Arizona • Oakland, California • San Ramon, California + 18 more

Conditions: Hepatitis A
Interventions: Havrix®, M-M-R®II, VARIVAX®; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Months to 13 Months
Enrollment: 1,474 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2009
U.S. locations: 42
States / cities: Cabot, Arkansas • Jonesboro, Arkansas • North Little Rock, Arkansas + 37 more

Conditions: Poliomyelitis, Postpoliomyelitis Syndrome
Interventions: Not listed
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: Not listed
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1982 – 2003
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Cerebrovascular Accident, Post-polio Syndrome, Spinal Cord Injuries, Multiple Sclerosis, Muscular Dystrophy, Paralysis
Interventions: Indego Nomad® Powered Knee-Ankle-Foot Orthosis (P-KAFO) (Parker Hannifin Corp., Cleveland, OH); Device
Lead sponsor: Shirley Ryan AbilityLab; Other
Eligibility: 18 Years to 89 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Poliomyelitis, Diphtheria, Haemophilus Influenzae Type b, Tetanus, Acellular Pertussis, Hepatitis B
Interventions: Infanrix hexa, Pediarix, ActHIB, Pentacel, Engerix-B, Infanrix, Hiberix, Prevnar13, Rotarix; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 6 Weeks to 12 Weeks
Enrollment: 585 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 43
States / cities: Tucson, Arizona • Fayetteville, Arkansas • Anaheim, California + 38 more

Conditions: Enterovirus, Rhinovirus
Interventions: Nitazoxanide, Placebo, Vitamin Super B-Complex; Drug · Dietary Supplement
Lead sponsor: Romark Laboratories L.C.; Industry
Eligibility: 12 Years to 120 Years
Enrollment: 214 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 3
States / cities: Hot Springs, Arkansas • Fort Lauderdale, Florida • The Bronx, New York

Conditions: Poliomyelitis
Interventions: Intradermal fractional dose inactivated polio vaccine (fIPV) in combination with recombinant double mutant heat labile toxin, LT(R192G/L211A), (dmLT), Intradermal fractional dose inactivated polio vaccine (fIPV), Monovalent oral poliomyelitis vaccine (mOPV), Sabin strain; Biological
Lead sponsor: University of Vermont; Other
Eligibility: 18 Years to 45 Years
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Burlington, Vermont

Conditions: Uveal Melanoma, Liver Metastases
Interventions: CVA21, Ipilimumab; Biological
Lead sponsor: Viralytics; Industry
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 3
States / cities: Miami Beach, Florida • Boston, Massachusetts

Conditions: Poliomyelitis
Interventions: Novel Oral Polio Vaccine Type 1 (nOPV1), Novel Oral Polio Vaccine Type 3 (nOPV3), Sabin Monovalent Oral Polio Vaccine Type 1 (mOPV1), Sabin Monovalent Oral Polio Vaccine Type 3 (mOPV3); Biological
Lead sponsor: PATH; Other
Eligibility: 18 Years to 45 Years
Enrollment: 226 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 4
States / cities: Baltimore, Maryland • Lebanon, New Hampshire • Chapel Hill, North Carolina + 1 more

Conditions: Hepatitis A
Interventions: GSK Biologicals 2-dose inactivated hepatitis A vaccine (Havrix), Prevnar™; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Months to 13 Months
Enrollment: 521 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2006
U.S. locations: 18
States / cities: Centennial, Colorado • Bardstown, Kentucky • Louisville, Kentucky + 13 more

Conditions: Diphtheria, Tetanus, Whooping Cough, Polio, Haemophilus Influenzae Type b
Interventions: DAPTACEL® (Diphtheria and Tetanus Toxoids and Acellular Pertussis vaccine), Pentacel: DTaP-IPV/Hib; Biological
Lead sponsor: Sanofi; Industry
Eligibility: 42 Days to 84 Days
Enrollment: 1,941 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001 – 2004
U.S. locations: 26
States / cities: Fayetteville, AR 72703, Arkansas • Jonesboro, AR 72401, Arkansas • Little Rock, AR 72211, Arkansas + 23 more

Conditions: Enterovirus Infection
Interventions: Placebo, Pleconaril; Other · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 0 Days to 15 Days
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2012
U.S. locations: 24
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 20 more

Search by objective public record fields.

Pentavalent DTaP-Hep B-IPV

Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin for the Treatment of HCV (ION-3)

Congenital Heart Anomaly Risk in Maternal Enteroviral Infection and Diabetes

Efficacy and Safety of Nitazoxanide in the Treatment of Colds Due to Enterovirus/Rhinovirus Infection

Study of the Efficacy and Safety of Immune Globulin Intravenous (Human) Flebogamma® 5% Dual Inactivation and Filtration (DIF) in Participants With Post-polio Syndrome

Study of DTap-IPV Compared to DAPTACEL® and IPOL® as the 5th Dose in Children 4 to 6 Years of Age

Modafinil to Treat Fatigue in Post-Polio Syndrome

Sucralfate to Improve Oral Intake in Children With Infectious Oral Ulcers: a Randomized, Double-blind, Placebo-Controlled Trial

Immunogenicity Study of an Inactivated Hepatitis A Vaccine in Infants and Young Children

Evaluation of Safety, Reactogenicity and Immunogenicity of Fractional-dose Inactivated Polio Vaccine (fIPV) Given Intradermally With Double Mutant Enterotoxigenic Escherichia Coli Heat Labile Toxin (dmLT) Adjuvant

Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination (FDC) With and Without Ribavirin for the Treatment of HCV

Immunogenicity and Safety of Havrix™ Co-Administered With a Diphtheria, Tetanus and Pertussis and a Haemophilus b Vaccine in Children Aged 15 Months

Immunogenicity & Safety of Hepatitis A Vaccine Co-admin With a Measles/Mumps/Rubella & a Varicella Vaccine in Children

Study of "Post-Polio Syndrome"

Nomad P-KAFO Study

Study to Determine the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals; Infanrix Hexa at 2, 4 and 6 Months of Age in Healthy Infants

Trial to Evaluate Efficacy and Safety of Nitazoxanide in the Treatment of Colds Due to Enterovirus/Rhinovirus Infection

Intradermal Fractional Dose IPV (fIPV) in Combination With dmLT

CAVATAK® and Ipilimumab in Uveal Melanoma Metastatic to the Liver (VLA-024 CLEVER)

Study of Novel Types 1 and 3 Oral Poliomyelitis Vaccines

Immune Response & Safety of a Hepatitis A Vaccine Given Together With a Pneumococcal Vaccine in Healthy Children 15 m of Age

Study of the Safety, Immunogenicity and Lot Comparability of DAPTACEL When Administered With Other Recommended Vaccine

Pleconaril Enteroviral Sepsis Syndrome